Comment on: Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial: reply.

Sircar, Geetabali; Goswami, Rudra Prosad; Sircar, Dipankar; Ghosh, Alakendu; Ghosh, Parasar

Sircar, Geetabali; Goswami, Rudra Prosad; Sircar, Dipankar; Ghosh, Alakendu; Ghosh, Parasar.

Afiliação

Sircar G; Department of Rheumatology, Institute of Postgraduate Medical Education and Research, Kolkata.
Goswami RP; Department of Rheumatology, Institute of Postgraduate Medical Education and Research, Kolkata.
Sircar D; Department of Nephrology, Institute of Postgraduate Medical Education and Research, Kolkata.
Ghosh A; Department of Rheumatology, Institute of Postgraduate Medical Education and Research, Kolkata.
Ghosh P; Department of Rheumatology, Institute of Postgraduate Medical Education and Research, Kolkata.

Rheumatology (Oxford) ; 58(5): 925-926, 2019 05 01.

Article em En | MEDLINE | ID: mdl-30809671

Assuntos

Pneumopatias; Esclerodermia Difusa; Anticorpos Monoclonais Murinos; Ciclofosfamida; Humanos; Rituximab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esclerodermia Difusa / Pneumopatias Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Rheumatology (Oxford) Assunto da revista: REUMATOLOGIA Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google